• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: 6-((6-aminopyridin-2-yl)methyl)-4-methyl-2-(1H-pyrazol-3-ylmethyl)-4,6-dihydro-5H-[1,3]thiazolo[5',4':4,5]pyrrolo[2,3-d] pyridazin-5-one
Date Designated: 09/09/2024
Orphan Designation: treatment of myelodysplastic syndromes (MDS)
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, Massachusetts 02139
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-